|1.||Kokudo, Norihiro: 9 articles (04/2012 - 05/2003)|
|2.||Kudo, Masatoshi: 8 articles (04/2012 - 12/2006)|
|3.||Kim, Do Young: 7 articles (03/2016 - 01/2007)|
|4.||Ahn, Sang Hoon: 7 articles (03/2016 - 01/2007)|
|5.||Han, Kwang-Hyub: 7 articles (03/2016 - 01/2009)|
|6.||Joh, Jae-Won: 7 articles (11/2015 - 06/2013)|
|7.||Kim, Jong Man: 6 articles (11/2015 - 06/2013)|
|8.||Taketomi, Akinobu: 6 articles (10/2015 - 12/2004)|
|9.||Kumada, Takashi: 6 articles (06/2014 - 09/2007)|
|10.||Toyoda, Hidenori: 6 articles (06/2014 - 09/2007)|
|1.||Hepatocellular Carcinoma (Hepatoma)
09/01/2008 - "A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma."
02/01/1995 - "Immunohistochemical studies of PIVKA-II in hepatocellular carcinoma by indirect immunofluorescence."
10/01/2015 - "Upregulation of des-gamma-carboxy-prothrombin after portal vein embolization in a cirrhotic patient with hepatocellular carcinoma."
04/01/2015 - "Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion."
12/01/2014 - "Evaluation of serum PIVKA-II and MIF as diagnostic markers for HCV/HBV induced hepatocellular carcinoma."
12/01/2001 - "There was no relationship between the expression of PIVKA-II in cancer tissues and serum levels of PIVKA-II. Immunohistochemical studies revealed that PIVKA-II was expressed even in small-sized or well-differentiated HCC cells, but expression was not detected in AH. "
01/01/2015 - "The expression of PIVKA-II was detected in non-cancer areas, with non-specific expression observed in plasma cells in our case. "
12/01/2014 - "Significant correlations were observed between STAT4 expression and tumor TNM stage (P = 0.043), hepatic venous invasion (P = 0.003), des-gamma-carboxy prothrombin (P = 0.011), tumor size (P = 0.036), and tumor differentiation (P = 0.034). "
04/14/2014 - "Increased PIVKA-II levels and small tumor size were associated with HCC recurrence in multivariate analysis. "
11/01/2013 - "The direct relation between the level of PIVKA-II and the size of tumor makes it an attractive tool for early HCC diagnosis and surveillance. "
|3.||Neoplasm Metastasis (Metastasis)
11/01/2009 - "In February 2005, the adrenal lesion enlarged to 5 cm in diameter and the value of PIVKA-II became high on blood examination, so April 2005, a surgical resection was performed, and it was diagnosed as the metastasis from HCC. "
12/01/2007 - "In PIVKA II-positive HCC, the frequencies of an infiltrative growth type (positive : negative = 62% : 28%, P < 0.001), vascular invasion (positive : negative = 63% : 26%, P < 0.001), and intrahepatic metastasis (positive : negative = 38% : 4%, P < 0.001) were significantly higher than in PIVKA II-negative HCC. "
01/01/2007 - "A univariate analysis revealed that Child-Pugh classification B (P = 0.002), a high des-gamma-carboxy prothrombin concentration (> or =400 mAU/ml, P = 0.023), a large HCC (> or =5.0 cm in diameter, P = 0.002), the presence of portal vein invasion (P < 0.001), the presence of venous trunk invasion (P = 0.048), the presence of intrahepatic metastasis (P < 0.001), and poorly differentiated HCC (P = 0.006) correlated with a worse overall survival after hepatic resection. "
10/01/2004 - "Soon after the treatments, PVTT was reduced in size and the serum level of PIVKA-II was decreased to 57 mAU/ml. After three months, the level of PIVKA-II had increased again and the size of the right adrenal metastasis grew to 50 mm in diameter. "
05/01/2011 - "With multivariate analysis, (1) preoperatively, positive factors of two or more among three items of PIVKA-II, L3-AFP, and deviancy from MC; (2) and postoperatively, pathological cancer spread (microscopic vascular invasion and/or intrahepatic metastasis) both represented risks for early recurrence. "
06/16/2003 - "However, only 13 patients with cirrhosis had higher PIVKA II levels. "
01/01/2002 - "Only 4 patients with cirrhosis had such high PIVKA II levels. "
01/01/2002 - "When the cutoff level of 40 mAU/ml was used as the level of discriminating HCC from cirrhosis, 51.7% of patients (31/60) with HCC had PIVKA II values above this level (sensitivity). "
01/01/2002 - "The mean serum concentration of PIVKA II in HCC patients (784.3 +/- 1364.1 mean +/- s) was higher than that in cirrhosis patients (16.1 +/- 31.7); this difference was highly significant (P < 0.0001). "
04/01/1993 - "3. An increase of descarboxylated prothrombin in plasma is also detected in the CCl4-liver fibrosis model."
|5.||P 11 (P-11)
|6.||Biological Tumor Markers (Tumor Markers)
|7.||Prothrombin (Factor II)
|8.||Proteins (Proteins, Gene)
|10.||Vitamin K 1 (Phylloquinone)
|3.||Surgical Instruments (Clip)